What is immunotherapy and how does it treat cancer and other conditions?
Immunotherapy is a biological treatment that utilizes the immune system to combat diseases, particularly cancer. Over the past decade, clinical trials for immunotherapies have surged, with a focus on various conditions beyond cancer, including infections and autoimmune disorders. Researchers are exploring how these therapies work and their potential to improve patient outcomes.
- ▪Clinical trials of immunotherapies have increased significantly, from 1,257 trials between 2006 and 2016 to 4,591 in the past decade.
- ▪Cancer patients have benefited from various immunotherapies, with dozens approved for over 30 types of cancer.
- ▪Research is ongoing to understand why some patients respond well to immunotherapy while others do not.
The Guardian — UK publishes from United Kingdom and files mainly under news. We currently carry 254 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | The Guardian — UK |
| Canonical URL | https://www.theguardian.com/science/2026/may/22/what-are-immunotherapies-and-how-do-they-treat-cancer-and-other-conditions |
| Publication time | Fri, 22 May 2026 14:00:01 GMT |
| Retrieval time | 2026-05-22T14:17:02.368Z |
| Last seen | 2026-05-22T14:17:04.242Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | qph56BznLQKb |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
A nurse preparing a new immunotherapy injection for more than a dozen cancers, at the Mount Vernon Cancer Centre in Hertfordshire. Photograph: Shivansh Gupta/PAView image in fullscreenA nurse preparing a new immunotherapy injection for more than a dozen cancers, at the Mount Vernon Cancer Centre in Hertfordshire. Photograph: Shivansh Gupta/PAImmunologyExplainerWhat is immunotherapy and how does it treat cancer and other conditions?From infections and allergies to brain diseases and autoimmune disorders, a wave of trials offers hopeIan Sample Science editorFri 22 May 2026 10.00 EDTLast modified on Fri 22 May 2026 10.01 EDTSharePrefer the Guardian on GoogleClinical trials of immunotherapies have rocketed in the past decade as researchers have turned their understanding of the body’s…
Excerpt limited to ~120 words for fair-use compliance. The full article is at The Guardian — UK.
Discussion
0 commentsMore from The Guardian — UK
